The Impact on Method Performance When mAb Are Removed from a Spectral Immunophenotyping Panel

monoclonal-antibody-blue-molecular-structure-illustration-for-cancer-treatment_adobestock_1331526674

Evaluate a fit-for-purpose approach to spectral flow cytometry panel design.

Selecting the appropriate flow cytometry panel requires balancing analytical performance with study objectives. This poster compares a comprehensive 26-color spectral immunophenotyping panel with a streamlined 13-color version, evaluating their performance, precision, and agreement to determine whether a reduced panel can support reliable clinical testing.

Key highlights include:

  • Comparison of 26-color and 13-color spectral immunophenotyping panels
  • Evaluation of assay precision and agreement across reportable cell populations
  • Assessment of panel performance using cryopreserved PBMC samples
  • Analysis of the impact of reducing monoclonal antibodies on data quality and resolution
  • Considerations for developing fit-for-purpose flow cytometry panels for clinical studies

As flow cytometry applications continue to evolve, fit-for-purpose panel design can help optimize study efficiency while maintaining robust analytical performance. Learn how streamlined panel strategies can support reliable immunophenotyping without compromising data quality.

Complete the form below to access this poster.

The Impact on Method Performance When mAb Are Removed from a Spectral Immunophenotyping Panel

To learn more about how Eurofins processes and protects your personal data and your rights, please read our Privacy Notice.